557. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 774 of 14 May 2026, whether the HSE produces prescribing trend analysis for nebulised bronchodilator medications at health region level; and if so, to provide that analysis for the period January to June 2026 broken down by health region. [66542/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
579. Deputy Aindrias Moynihan asked the Minister for Health to provide the current stage on the HSE assessment of a medication (details supplied); to confirm when the HSE's Drugs Group will issue their recommendation to the HSE Senior Management Team to progress the reimbursement decision on this medication; and if she will make a statement on the matter. [66640/26]
588. Deputy David Maxwell asked the Minister for Health the reason tirzepatide (Mounjaro), despite being authorised for the treatment of type 2 diabetes, is not currently covered under the medical card, long-term illness scheme or drugs payment scheme; and if she will outline the current position regarding access to this medication through the State schemes. [66674/26]
625. Deputy Catherine Callaghan asked the Minister for Health if she will provide an update on the progress of the Full Health Technology Assessment (HTA) for a drug (details supplied) for the treatment of eosinophilic oesophagitis, which was commissioned by the HSE on 25 June 2024, when the assessment is expected to be completed and whether consideration is being given to making this drug available under the Medical…
671. Deputy Denise Mitchell asked the Minister for Health for an update on the consideration for medications (details supplied) to be included in the drugs payment scheme, specifically in relation to their usage for weight management in patients at risk of developing type two diabetes. [67224/26]
330. Deputy Séamus McGrath asked the Minister for Health if she will please give consideration to adding the medication (EURNeffy) (details supplied) which is used to treat life threatening allergies to the list of reimbursement medicines under the drugs payment scheme; and if she will provide a statement on the matter. [66001/26]
357. Deputy Cormac Devlin asked the Minister for Health the number of outstanding legal actions involving a medication (details supplied) and associated costs paid from 2018 to 1 July 2026. [66063/26]
363. Deputy Seán Ó Fearghaíl asked the Minister for Health if she is aware of concerns raised by patients and families affected by phenylketonuria (PKU) regarding access to a medicinal product (details supplied); if the product has been assessed, or is under assessment, for reimbursement and availability in Ireland; the current status of any application for pricing and reimbursement of this treatment; and the timelin…
364. Deputy Marie Sherlock asked the Minister for Health the name of each cancer specific drug currently being administered with the support of private insurance in acute hospitals. [66175/26]
366. Deputy Marie Sherlock asked the Minister for Health the name of each cancer specific drug that was approved by HSE’s EMT for approval for each of the years 2019 to date in 2026. [66173/26]
370. Deputy Marie Sherlock asked the Minister for Health the name of each cancer specific drug that was submitted to the HSE’s EMT for approval for each of the years 2019 to date in 2026. [66169/26]
372. Deputy Marie Sherlock asked the Minister for Health the number of new cancer specific drugs approved for reimbursement by the HSE for each of the years 2019 to date in 2026. [66166/26]
375. Deputy Marie Sherlock asked the Minister for Health the names of cancer specific drugs being administered via a clinical trial in 2026. [66189/26]
377. Deputy Marie Sherlock asked the Minister for Health the number of cancer specific drugs being administered via a clinical trial for each of the years from 2019 to date in 2026. [66187/26]
380. Deputy Marie Sherlock asked the Minister for Health the name of each non cancer specific drug that is being administered with the support of private insurance in acute hospitals in 2026. [66184/26]
382. Deputy Marie Sherlock asked the Minister for Health the number of non cancer specific drugs being administered with the support of private insurance in acute hospitals for each of the years 2019 to date in 2026. [66181/26]
386. Deputy Marie Sherlock asked the Minister for Health the number of cancer specific drugs being administered with the support of private insurance in acute hospitals for each of the years 2019 to date in 2026. [66177/26]
414. Deputy John Clendennen asked the Minister for Health for an update on the reimbursement of belzutifan, for the treatment of von Hippel-Lindau (VHL) disease, by the HSE; whether the application is being assessed on the most up to date information on the performance of the drug and subsequent patient outcomes; and when a final decision is likely. [66250/26]
416. Deputy John Clendennen asked the Minister for Health whether the pharmacoeconomic and reimbursement assessment of belzutifan for von Hippel Lindau disease takes account of the full long-term healthcare costs associated with the natural progression of the disease and repeated treatment of VHL-associated tumors including renal surgery, loss of renal function, chronic kidney disease, dialysis, renal transplantation…
1111. Deputy Paul Nicholas Gogarty asked the Minister for Health the engagement that has taken place between her Department, the HSE, clinicians, patient organisations and the manufacturer of a medication (details supplied) regarding access to the treatment of patients with Von Hippel-Lindau (VHL) disease; whether interim or compassionate access arrangements are being considered pending a reimbursement decision; and …
1112. Deputy Paul Nicholas Gogarty asked the Minister for Health the steps being taken by her Department and the HSE to ensure timely and equitable access to a medication (details supplied) for eligible patients with Von Hippel-Lindau (VHL) disease, in view of its potential to reduce the need for repeated surgeries and improve quality of life; and if she will make a statement on the matter. [64204/26]
1113. Deputy Paul Nicholas Gogarty asked the Minister for Health the current status of the assessment, appraisal and reimbursement process for a medication (details supplied) for the treatment of patients with Von Hippel-Lindau (VHL) disease; the timeline for a decision on its approval and reimbursement; and if she will make a statement on the matter. [64203/26]
1160. Deputy Willie O'Dea asked the Minister for Health if she will consider making the testing of lipoprotein available to general practitioners given this will help to identify individuals who are at high risk for developing cardiovascular disease due to the nature of their genetics; and if she will make a statement on the matter. [64362/26]
1174. Deputy Naoise Ó Muirí asked the Minister for Health if the HSE intends to add amivantamab, which has been approved by the European Medicines Agency, to the list of reimbursable medicines (details supplied); and if she will make a statement on the matter [64521/26]
1178. Deputy Pádraig O'Sullivan asked the Minister for Health the average length of time between European Medicines Agency approval and reimbursement approval in Ireland for rare disease and orphan medicines; and the way in which this compares with other EU countries. [64549/26]